Johnson & Johnson (JNJ) Other financing activities (2009 - 2026)

Johnson & Johnson has reported Other financing activities for 15 years, with the latest figure at -$588.0 million in Q1 2026.

• Quarterly Other financing activities fell 1570.0% year-over-year to -$588.0 million in Q1 2026, while the trailing twelve-month figure through Jun 2026 was -$663.0 million (down 1850.0% YoY) and the FY2025 annual result came in at -$34.0 million, up 10.53% from the prior year.
• Other financing activities eased to -$588.0 million in Q1 2026 per JNJ's latest filing, from -$26.0 million in the prior quarter.
• Over five years, Other financing activities peaked at $4.5 billion in Q3 2023 and troughed at -$588.0 million in Q1 2026.
• A 5-year average of $286.2 million and a median of -$37.5 million in 2025 frame the typical range for Other financing activities.
• The sharpest annual moves came in 2024 and 2026: Other financing activities soared 138.91% in 2024, then sank 1570.0% in 2026.
• Over 5 years, Other financing activities stood at -$138.0 million in 2022, then jumped by 3346.38% to $4.5 billion in 2023, then slumped by 101.67% to -$75.0 million in 2024, then jumped by 65.33% to -$26.0 million in 2025, then slumped by 2161.54% to -$588.0 million in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered -$588.0 million, -$26.0 million, and -$49.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.